Ezetimibe and vascular endothelial function.
スポンサーリンク
概要
- 論文の詳細を見る
Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver. Statins also have beneficial pleiotropic effects on the atherosclerotic process that are independent of their ability to lower lipid values. However, the levels of low-density lipoprotein cholesterol (LDL-C) in most hypercholesterolemic patients at high risk for cardiovascular disease do not reach the goals proposed by guidelines even when prescribed with statins. Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins. However, its effect on cardiovascular events remains unknown. We reviewed the effects of ezetimibe on cardiovascular diseases, in particular, vascular endothelial function, which is initially impaired during the atherogenetic process and is an important predictor of cardiovascular events. The simultaneous inhibition of cholesterol synthesis by statin and of cholesterol absorption by ezetimibe might retard the atherogenetic process. These effects are considered to be mainly mediated by lipid lowering. However, further studies should elucidate the mechanism of the anti-atherosclerotic effects induced by ezetimibe; for instance, whether or not it directly affects atherogenesis independently from its lipid-lowering effects.
論文 | ランダム
- P0M材のクリープ変形特性に対する先行繰返し予変形の影響
- 組合せ引張り-ねじり状態における結晶性高分子POM材の繰返し応力・ひずみ関係
- プラズマ照射医薬品添加物を利用する DDS の新展開1)
- 極低温ボース・フェルミ混合原子気体での集団運動の研究(大振幅集団運動の微視的理論,研究会報告)
- 分子レベルの放射性炭素同位体分析を用いた化学物質の環境動態解析